Insmed ceo lobbies for follow-on biologics rule

WASHINGTON The chief executive of a biotech company in Richmond, Va., wants to make it possible to get generic biologic drugs approved, the Washington Post reported Wednesday.

Geoffrey Allan, chief executive officer of Insmed, has been lobbying members of Congress in an effort to teach them the differences between chemical and biotech drugs. Allan hopes his company will become the first United States company to develop generic biologic drugs, also called “biosimilars.”

While the market for generic chemical drugs is expanding, there is no way to get generic biologic drugs approved. Allan hopes that Congress will change the laws to make generic biologic drug competition possible.